Song Shangqing, Wu Zhenjie, Wang Cheng, Liu Bing, Ye Xuerong, Chen Junming, Yang Qing, Ye Huamao, Xu Bin, Wang Linhui
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, P.R. China.
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, P.R. China.
Urology. 2014 Sep;84(3):730.e1-7. doi: 10.1016/j.urology.2014.05.033.
To investigate the expression pattern of a novel long noncoding ribonucleic acid (RNA), RCCRT1, in renal cell carcinoma (RCC) tissues among the patients with various clinicopathologic features and to detect the role of RCCRT1 in migration and invasion of RCC in vitro.
We found out a novel long noncoding RNA, RCCRT1, that expressed differently between high-grade (Fuhrman grade III-IV) and low-grade RCC tissues (Fuhrman grade I-II) by gene chip analysis, then verified it with quantitative polymerase chain reaction. The expression of RCCRT1 was diminished by transfecting with small interfering RNA. RCCRT1 effects were assessed by cell proliferation, cell apoptosis, transwell assay, and wound-healing assay.
Compared with adjacent noncancerous tissues, RCCRT1 is upregulated remarkably in RCC, particularly in high-grade RCC tissues. After analyzing the relative expression of RCCRT1 in various tissues by quantitative reverse transcription polymerase chain reaction and clinicopathologic characteristics of patients, we drew the conclusion that RCCRT1 is associated with clinicopathologic findings such as tumor size, pathologic T stage, tumor grade, lymph node metastasis, and distant metastasis. Furthermore, small interfering RNA-induced depletion of RCCRT1 expression suppressed migration and invasion in RCC cell lines.
The results of the present study suggest that RCCRT1 promoted migration and invasion of RCC and that RCCRT1 may offer a biomarker to verdict prognosis as well as an attractive new target for prognostic and therapeutic intervention for RCC patients in the future.
研究一种新型长链非编码核糖核酸（RNA）RCCRT1在具有不同临床病理特征的肾细胞癌（RCC）组织中的表达模式，并检测RCCRT1在体外对RCC迁移和侵袭的作用。
通过基因芯片分析，我们发现一种新型长链非编码RNA RCCRT1，其在高级别（Fuhrman分级III-IV级）和低级别RCC组织（Fuhrman分级I-II级）中表达不同，随后用定量聚合酶链反应进行验证。通过转染小干扰RNA降低RCCRT1的表达。通过细胞增殖、细胞凋亡、Transwell实验和伤口愈合实验评估RCCRT1的作用。
与癌旁组织相比，RCCRT1在RCC中显著上调，尤其是在高级别RCC组织中。通过定量逆转录聚合酶链反应分析RCCRT1在各种组织中的相对表达以及患者的临床病理特征后，我们得出结论，RCCRT1与肿瘤大小、病理T分期、肿瘤分级、淋巴结转移和远处转移等临床病理结果相关。此外，小干扰RNA诱导的RCCRT1表达缺失抑制了RCC细胞系的迁移和侵袭。
本研究结果表明，RCCRT1促进了RCC的迁移和侵袭，并且RCCRT1可能为判断预后提供一个生物标志物，同时在未来为RCC患者的预后和治疗干预提供一个有吸引力的新靶点。
